After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
But the Astra/Daiichi ADC stumbles in lung cancer.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company quietly deprioritises AlphaMedix.
The company is starting four new pivotal trials this year.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Tecvayli and Hernexeos might get speedy approval decisions.
